Back to Search Start Over

Machine learning analysis of humoral and cellular responses to SARS-CoV-2 infection in young adults.

Authors :
Marcinkevics R
Silva PN
Hankele AK
Dörnte C
Kadelka S
Csik K
Godbersen S
Goga A
Hasenöhrl L
Hirschi P
Kabakci H
LaPierre MP
Mayrhofer J
Title AC
Shu X
Baiioud N
Bernal S
Dassisti L
Saenz-de-Juano MD
Schmidhauser M
Silvestrelli G
Ulbrich SZ
Ulbrich TJ
Wyss T
Stekhoven DJ
Al-Quaddoomi FS
Yu S
Binder M
Schultheiß C
Zindel C
Kolling C
Goldhahn J
Seighalani BK
Zjablovskaja P
Hardung F
Schuster M
Richter A
Huang YJ
Lauer G
Baurmann H
Low JS
Vaqueirinho D
Jovic S
Piccoli L
Ciesek S
Vogt JE
Sallusto F
Stoffel M
Ulbrich SE
Source :
Frontiers in immunology [Front Immunol] 2023 May 29; Vol. 14, pp. 1158905. Date of Electronic Publication: 2023 May 29 (Print Publication: 2023).
Publication Year :
2023

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces B and T cell responses, contributing to virus neutralization. In a cohort of 2,911 young adults, we identified 65 individuals who had an asymptomatic or mildly symptomatic SARS-CoV-2 infection and characterized their humoral and T cell responses to the Spike (S), Nucleocapsid (N) and Membrane (M) proteins. We found that previous infection induced CD4 T cells that vigorously responded to pools of peptides derived from the S and N proteins. By using statistical and machine learning models, we observed that the T cell response highly correlated with a compound titer of antibodies against the Receptor Binding Domain (RBD), S and N. However, while serum antibodies decayed over time, the cellular phenotype of these individuals remained stable over four months. Our computational analysis demonstrates that in young adults, asymptomatic and paucisymptomatic SARS-CoV-2 infections can induce robust and long-lasting CD4 T cell responses that exhibit slower decays than antibody titers. These observations imply that next-generation COVID-19 vaccines should be designed to induce stronger cellular responses to sustain the generation of potent neutralizing antibodies.<br />Competing Interests: CD, MSc, BS, PZ, FH, AR, Y-JH, GL, and HB are employees of Miltenyi Biotec B.V. & Co. KG. LP is an employee of Humabs BioMed SA, a subsidiary of Vir Biotechnology. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Marcinkevics, Silva, Hankele, Dörnte, Kadelka, Csik, Godbersen, Goga, Hasenöhrl, Hirschi, Kabakci, LaPierre, Mayrhofer, Title, Shu, Baiioud, Bernal, Dassisti, Saenz-de-Juano, Schmidhauser, Silvestrelli, Ulbrich, Ulbrich, Wyss, Stekhoven, Al-Quaddoomi, Yu, Binder, Schultheiβ, Zindel, Kolling, Goldhahn, Seighalani, Zjablovskaja, Hardung, Schuster, Richter, Huang, Lauer, Baurmann, Low, Vaqueirinho, Jovic, Piccoli, Ciesek, Vogt, Sallusto, Stoffel and Ulbrich.)

Details

Language :
English
ISSN :
1664-3224
Volume :
14
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
37313411
Full Text :
https://doi.org/10.3389/fimmu.2023.1158905